Skip to main content
SpringerLink
Log in

Careful management can reduce the risk of bleeding in elderly patients receiving vitamin K antagonist (VKA) therapy

  • Drug Reactions and Interaction
  • Published:
Drugs & Therapy Perspectives Aims and scope Submit manuscript

    We’re sorry, something doesn't seem to be working properly.

    Please try refreshing the page. If that doesn't work, please contact support so we can address the problem.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Table II
Table III
Table IV

References

  1. Pautas E, Gouin-Thibault I, Debray M, et al. Haemorrhagic complications of vitamin K antagonists in the elderly: risk factors and management. Drugs Aging 2006; 23 (1): 13–25

    Google Scholar 

  2. Gross CP, Vogel EW, Dhond AJ, et al. Factors influencing physicians’ reported use of anticoagulation therapy in nonvalvular atrial fibrillation: a cross-sectional survey. Clin Ther 2003; 25(6): 1750–64

    Article  PubMed  Google Scholar 

  3. A randomized trial of anticoagulants versus aspirin after cerebral ischemia of presumed arterial origin: the Stroke Prevention in Reversible Ischemia Trial (SPIRIT) Study Group. Ann Neurol 1997; 42 (6): 857-65

  4. Go AS, Hylek EM, Chang Y, et al. Anticoagulation therapy for stroke prevention in atrial fibrillation: how well do randomized trials translate into clinical practice? JAMA 2003; 290: 2685–92

    Article  PubMed  CAS  Google Scholar 

  5. Beyth RJ, Quinn LM, Landefeld CS. Prospective evaluation of an index for predicting the risk of major bleeding in outpatients treated with warfarin. Am J Med 1998; 105(2): 91–9

    Article  PubMed  CAS  Google Scholar 

  6. Kuijer PM, Hutten BA, Prins MH, et al. Prediction of the risk of bleeding during anticoagulant treatment for venous thromboembolism. Arch Intern Med 1999; 159(5): 457–60

    Article  PubMed  CAS  Google Scholar 

  7. Gage BF, Yan Y, Milligan PE, et al. Clinical classification schemes for predicting hemorrhage: results from the National Registry of Atrial Fibrillation (NRAF). Am Heart J 2006; 151(3): 713–9

    Article  PubMed  Google Scholar 

  8. Kagansky N, Knobler H, Rimon E, et al. Safety of anticoagulation therapy in well-informed older patients. Arch Intern Med 2004; 164(18): 2044–50

    Article  PubMed  Google Scholar 

  9. Man-Son-Hing M, Nichol G, Lau A, et al. Choosing antithrombotic therapy for elderly patients with atrial fibrillation who are at risk for falls. Arch Intern Med 1999; 159(7): 677–85

    Article  PubMed  CAS  Google Scholar 

  10. Ufer M. Comparative pharmacokinetics of vitamin K antagonists: warfarin, phenprocoumon and acenocoumarol. Clin Pharmacokinet 2005; 44(12): 1227–46

    Article  PubMed  CAS  Google Scholar 

  11. Ansell J, Hirsh J, Poller L, et al. The pharmacology and management of the vitamin K antagonists: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126(3 Suppl.): 204S–33S

    Article  PubMed  CAS  Google Scholar 

  12. Froom P, Miron E, Barak M. Oral anticoagulants in the elderly. Br J Haematol 2003; 120(3): 526–8

    Article  PubMed  Google Scholar 

  13. Wehinger C, Stollberger C, Langer T, et al. Evaluation of risk factors for stroke/embolism and of complications due to anticoagulant therapy in atrial fibrillation. Stroke 2001; 32(10): 2246–52

    Article  PubMed  CAS  Google Scholar 

  14. Siguret V, Esquirol C, Debray M, et al. Excess antivitamin K in elderly hospitalised patients aged over 70. A one-year prospective survey [in French]. Presse Med 2003; 32(21): 972–7

    PubMed  CAS  Google Scholar 

  15. Shireman TI, Howard PA, Kresowik TF, et al. Combined anticoagulant-antiplatelet use and major bleeding events in elderly atrial fibrillation patients. Stroke 2004; 35(10): 2362–7

    Article  PubMed  CAS  Google Scholar 

  16. Holbrook AM, Pereira JA, Labiris R, et al. Systematic overview of warfarin and its drug and food interactions. Arch Intern Med 2005; 165: 1095–106

    Article  PubMed  CAS  Google Scholar 

  17. Siguret V, Gouin I, Debray M, et al. Initiation of warfarin therapy in elderly medical inpatients: a safe and accurate regimen. Am J Med 2005; 118: 137–42

    Article  PubMed  CAS  Google Scholar 

  18. Roberts GW, Druskeit T, Jorgensen LE, et al. Comparison of an age adjusted warfarin loading protocol with empirical dosing and Fennerty’s protocol. Aust N Z J Med 1999 Oct; 29(5): 731–6

    Article  PubMed  CAS  Google Scholar 

  19. Roberts GW, Helboe T, Nielsen CB, et al. Assessment of an age-adjusted warfarin initiation protocol. Ann Pharmacother 2003 Jun; 37(6): 799–803

    Article  PubMed  CAS  Google Scholar 

  20. Gage BF, Eby C, Milligan PE, et al. Use of pharmacogenetics and clinical factors to predict the maintenance dose of warfarin. Thromb Haemost 2004; 91(1): 87–94

    PubMed  CAS  Google Scholar 

  21. Khan TI, Kamali F, Kesteven P, et al. The value of education and self-monitoring in the management of warfarin therapy in older patients with unstable control of anticoagulation. Br J Haematol 2004; 126(4): 557–64

    Article  PubMed  Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Careful management can reduce the risk of bleeding in elderly patients receiving vitamin K antagonist (VKA) therapy. Drugs Ther. Perspect 22, 23–26 (2006). https://doi.org/10.2165/00042310-200622120-00008

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00042310-200622120-00008

Search

Navigation